In the era of genetic and molecular medicine, gene-editing technologies such as CRISPR-Cas9 aim to permanently eliminate the HIF-1α gene (220), thereby reducing tumor growth and enhancing T cell-mediated immunity. Here, HIF1A is linked to neoplasm.